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Chimeric antigen receptor (CAR) therapy is a promising immunotherapeutic strategy for
treating multiple refractory blood cancers, but further advances are required for solid tumor
CAR therapy. One challenge is identifying a safe and effective tumor antigen. Here, we devise
a strategy for targeting hepatocellular carcinoma (HCC, one of the deadliest malignancies).
We report that T and NK cells transduced with a CAR that recognizes the surface marker,
CD147, also known as Basigin, can effectively kill various malignant HCC cell lines in vitro,
and HCC tumors in xenograft and patient-derived xenograft mouse models. To minimize any
on-target/off-tumor toxicity, we use logic-gated (log) GPC3–synNotch-inducible CD147-CAR
to target HCC. LogCD147-CAR selectively kills dual antigen (GPC3+CD147+), but not single
antigen (GPC3-CD147+) positive HCC cells and does not cause severe on-target/off-tumor
toxicity in a human CD147 transgenic mouse model. In conclusion, these findings support the
therapeutic potential of CD147-CAR-modified immune cells for HCC patients.
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Despite recent advances in chimeric antigen receptor(CAR)-T cell immunotherapy in blood cancers, highcosts, complex manufacturing processes, and severe
toxicity have hindered its widespread use1. Meanwhile, CAR-T
cells face additional challenges during the targeting of solid
tumors, such as identification of a safe and effective solid tumor
antigen and maintenance of durable CAR cell proliferation and
persistence in the tumor microenvironment2,3. Among the var-
ious solid tumors in humans, liver cancer is one of the deadliest
tumors.
Liver cancer is the second most common cause of cancer-
related death worldwide4. The burden of liver cancer is projected
to be over 1 million cases by 20305. Liver cancer ranks fifth in
terms of global cases and second in terms of deaths for males6.
More than half a million patients die from hepatocellular carci-
noma (HCC) each year7.
Primary liver cancer comprises of HCC, intrahepatic cho-
langiocarcinoma (iCCA), fibrolamellar carcinoma, and hepa-
toblastoma4. HCC and iCCA are the most common primary
liver cancers, which account for >99% of primary liver cancer
cases4. There are nearly 800,000 new HCC cases per year and
HCC alone accounts for 90% of all cases of primary liver
cancer8.
Although liver cancer can be classified into several different
types, HCC is the most common type of primary liver cancer in
adults9. HCC is related to chronic viral hepatitis infection
(including hepatitis B and C) and toxic exposure (e.g., aflatoxin
B1)10. Currently, there is no effective therapy available to treat
HCC. Sorafenib (CheckMate-040, a multikinase inhibitor) is a
widely used first-line standard systemic agent for advanced
HCC11, but has been shown to have low efficacy and severe side
effects12–19. Currently, PD-1 blockade Opdivo (Nivolumab) has
been approved by the US Food and Drug Administration as a
second-line treatment strategy for patients with HCC who have
been previously treated with Sorafenib20. Clinical trials testing
PD-1 blockade as a first-line treatment for HCC are underway21.
Meanwhile, various clinical trials using PD-1 or PD-L1 blockades
in combination with other interventions are ongoing as well. For
example, a current study is evaluating an anti-PD-1 antibody in
combination with an anti-CTLA-4 antibody in patients with
resectable and potentially resectable HCC (NCT03222076).
CAR-T cell therapy has become a promising immunother-
apeutic strategy for the treatment of various blood cancers3.
CAR-modified immune cells for liver cancer therapy are rapidly
being developed in both academic settings and in industry22,23.
One remaining challenge for CAR-mediated immunotherapy for
liver cancer (one of the deadliest solid tumors in humans) is to
find a valid, safe, and effective target.
Current adoptive CAR-modified immune cell therapies for
HCC mainly target three antigens: glypican-3 (GPC3,
NCT02723942, NCT02905188, NCT02395250, NCT03146234,
NCT03084380, NCT02715362, NCT03198546, NCT03302403),
α-fetoprotein (AFP, NCT03349255), and mucin-1 (MUC1,
NCT02587689).
In addition to GPC3-CAR24,25, AFP-CAR26, and MUC1-
CAR27,28 for HCC immunotherapy, adoptive TCR-T cells have
also been investigated in the treatment of HCC29,30, which
includes HBV-specific TCR in HCC patients with HBV infection
(NCT02686372, NCT02719782) and AFP-specific TCR
(NCT03132792) in advanced HCC patients.
Dual-targeting CAR-T cells coexpressing GPC3 and asia-
loglycoprotein receptor 1 (ASGR1, a liver tissue-specific protein)
targeting CAR’s featuring CD3 zeta chain (CD3ζ) and 28BB
(containing both CD28 and 4-1BB signaling domains) have been
tested in a GPC3+ASGR1+ HCC tumor xenograft mouse
model31.
CD147 is a transmembrane glycoprotein with multiple func-
tions in immune cell biology and diseases32. The immunological
role of CD147 in immune cells is important for T cell activation
and proliferation, as well as cell migration, adhesion, and inva-
sion32. CD147 is expressed on different cell types (e.g., hemato-
poietic, epithelial, and endothelial cells) at varying levels33.
Normal epithelial and fetal tissues have low expression of CD147,
when measured by immunohistochemical analysis34. However,
CD147 is significantly upregulated in aggressive disease states,
such as in HCC35,36. Different groups have observed CD147
upregulation in various tumors37,38, including breast cancer,
bladder cancer, colorectal cancer, ovarian cancer, melanoma, and
osteosarcoma. In the past few decades, the role of CD147 has
been extensively studied in tumor biology with a focus on tumor
cell proliferation, invasiveness, and metastasis39,40. The proposed
molecular mechanism of CD147 in cancer is that CD147 on
the surface of tumor cells can trigger the production of matrix
metalloproteinase (a family of secreted, zinc-dependent endo-
peptidases capable of degrading extracellular matrix compo-
nents), which facilitates tumor invasion, growth, and
metastasis41–43.
Previous studies show that CD147 overexpression may be
associated with tumor cell migration and activation of the
extracellular-signal-regulated kinase signaling pathway44. CD147
has also been proposed as a novel prognostic biomarker for
HCC36. Specifically, development of a 131I-labeled HAb18 F(ab′)2
(Licartin) has been reported as a potential treatment option for
liver cancer. Clinical trial results show that Licartin is safe and
effective in patients with primary HCC45.
Preclinical studies conducted in China show that metuzumab
(anti-CD147) for the treatment of non-small cell lung cancer is
safe. Metuzumab exhibits promising efficacy in inhibiting tumor
growth in mouse xenograft models46.
Despite recent advances in CAR-T cell immunotherapy, high
costs and severe toxicity have hindered its widespread use3. To
alleviate these disadvantages of CAR-T cell immunotherapy,
additional cytotoxic cell-mediated immunotherapies are urgently
needed. The unique biology of natural killer (NK) cells allows
them to serve as a safe, effective, alternative, and possibly superior
immunotherapeutic strategy to CAR-T cells, clinically47. There-
fore, in addition to T cell-mediated immunotherapy, CAR-NK
cells may serve as a valid tool for immunotherapy48.
In this study, we hypothesize that immune cells, including T
and NK cells, expressing a CD147-targeting CAR can mount a
sustained anti-CD147+ HCC immune response. The biological
properties of the CD147 antigen allow CD147-CAR-modified
immune cells, including primary CD8+ T, primary NK, and NK-
92MI cells, to produce potent anti-tumor activity against HCC
in vitro and in vivo. Moreover, a synthetic Notch (synNotch)
receptor “logic-gated” CD147-CAR targeting both GPC3 and
CD147 is developed for minimizing potential toxicity in a human
CD147 transgenic (hCD147TG) mouse model. Together, the data
support the clinical development of CD147-CAR immune cell
therapy for various CD147+ solid tumors.
Results
CD147 is expressed in HCC cell lines and patient specimens.
To determine whether CD147 is an effective, valid target for HCC
and other types of cancers, we analyzed the correlation between
patient survival and expression level of CD147 from TCGA (The
Cancer Genome Atlas, https://cancergenome.nih.gov) datasets.
Comparison of survival percentages from two different patient
subsets (CD147high and CD147low) showed that there was a
strong negative correlation between CD147 expression and
overall survival (Supplementary Fig. 1a). Specifically, CD147high
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in multiple tumor tissues were correlated with a lower survival
percentage. In addition, comparisons of CD147 expression
between normal tissues (NTs) and tumor patient (TP) samples
across multiple cancer types showed significant upregulations of
CD147 expression among different types of tumor tissues (Sup-
plementary Fig. 1b).
To verify the data from the bioinformatics analysis, we
examined the expression of CD147 among different tumor cell
lines and other tissues by Western blot (WB), including wild-type
NK-92 (a human NK cell line49), T2 (a mutant T × B cell
hybrid50), 721.221 (a human leukocyte antigen (HLA)-A, -B, -C-
null human cell line51,52), MDA-MB-231 (a human breast
carcinoma cell line53), K562 (a human myelogenous leukemia
cell line54), HepG2 (a human HCC cell line55), SK-Hep1 (a
human liver adenocarcinoma cell line56), Raji (a human B
lymphocyte, Burkitt’s lymphoma cell line57), Daudi (a human B
lymphoblast cell line58), NK-92MI (an interleukin-2 (IL-2)-
independent natural killer cell line59), and human peripheral
blood mononuclear cells (PBMCs). CD147 molecules were highly
upregulated in HepG2 and SK-Hep1 cell lines (two commonly
used HCC cell lines), compared to PBMCs (Supplementary
Fig. 1c). The expression of CD147 on PBMCs is relatively low,
compared to tumor cell lines (Supplementary Fig. 1c). Similar
results were obtained by flow cytometry analysis (Supplementary
Fig. 1d). Furthermore, the results of immunohistochemistry
(IHC) assays confirmed that CD147 was significantly upregulated
in human HCC tissue isolated from a PDX mouse model
(Supplementary Fig. 2). Therefore, CD147 molecules could
represent an effective, valid target for HCC treatment.
Generation and phenotype of CD147-CAR-NK cells. To test the
susceptibility of HCC to CD147-CAR, we generated the CD147-
CAR using the SFG retroviral vector60,61. The CD147-CAR
contains the single-chain variable fragment (scFv) of the anti-
CD147 antibody (derived from clone 5F6 with optimization), a
human IgG1-CH2CH3 spacer, transmembrane domain of CD28,
the intracellular domain of CD28-4-1BB, and intracellular sig-
naling domains of the TCR-ζ chain (Supplementary Fig. 3a). First,
we tested this CAR construct using NK-92MI cells49,59,62. After
transduction, NK-92MI cells expressed the CD147-CAR mole-
cules (Supplementary Fig. 3b). After sorting by flow cytometry,
the percentage of CD147-postive NK-92MI cells was >96%
(Supplementary Fig. 3b). We further verified the expression of
CD147-CAR molecules in NK-92MI cells by WB. Compared to
the parental NK-92MI cell, the CD147-CAR-NK-92MI expressed
the chimeric anti-CD147-scFv-CAR. The approximate molecular
weight was ~80 to 85 kDa (Supplementary Fig. 3c). We further
characterized the surface immunophenotype in CD147-CAR-
NK-92MI cells. Comparable activating receptor (e.g., CD56,
NKG2D, NKP46, CD16, CD94/NKG2C, CD226 [also known as
DNAM-1], and CD244 [also known as 2B4]) and inhibitory
receptor (e.g., KLRG1, LAG-3, CTLA-4, TIM-3, PD-1, NKG2A,
and TIGIT) expressions were observed (Supplementary Fig. 3d).
CD147-CAR expression was associated with loss of CD147 or
decreased CD147 expression on CD147-CAR-NK-92MI cells,
indicating limited fratricide among CD147-CAR-NK-92MI cells
(Supplementary Fig. 4). Notably, the loss of CD147 molecule
expression on CD147-CAR-NK-92MI cells did not affect their
functionalities and expansion in vitro. Thus, we successfully
established a CD147-CAR-NK-92MI cell line for further study.
CD147+ HCC cell lines activate CD147-CAR-NK cells. After
successful establishment of CD147-CAR-NK cells, we then eval-
uated the capacity of CD147-CAR-NK-92MI cells to eradicate
CD147+ HCC cell lines (including SK-Hep1 and HepG2 cells).
Compared with control CD19-CD28-CAR-NK-92MI and CD19-
CD28-4-1BB-CAR-NK-92MI cells, as described previously61,
CD147-CAR-NK-92MI cells demonstrated significant cytotoxi-
city against several HCC cell lines, including SK-Hep1 and
HepG2 (Fig. 1a, b), as well as Huh7 and HCO2 cell lines com-
pared to parental NK-92MI cells (Supplementary Fig. 5).
The production of tumor necrosis factor alpha (TNF-α) and
interferon-γ (IFNγ) were greatly induced in CD147-CAR-NK-
92MI cells, comparing to CD19-CD28-CAR-NK-92MI and
CD19-CD28-4-1BB-CAR-NK-92MI cells stimulated by both
SK-Hep1 and HepG2 cells (Fig. 1c, d). Interestingly, activation
of CD147-CAR-NK-92MI cells by their susceptible target cells
can be blocked by the anti-CD147 antibody (clone HIM6), but
not the isotype IgG1 (Fig. 1e–g). The specificity of this anti-
CD147 antibody was further verified by testing its effects on
cytotoxicity of CD19-CD28-4-1BB-CAR-NK-92MI cells. We
showed that this anti-CD147 antibody could not block the
cytotoxicity of CD19-CD28-4-1BB-CAR-NK-92MI cells against
CD19+ Daudi cell line (Supplementary Fig. 6), indicating that the
anti-CD147 antibody (clone HIM6) did not affect other types of
CAR-NK cells (e.g., CD19-CD28-4-1BB-CAR cells), but specifi-
cally competed with CD147-CAR to recognize the target tumor
antigen.
To further confirm the specificity of CD147-CAR-NK-92MI
cells, we generated the CD147-knockout (CD147−/−) SK-Hep1
cell line (CD147−/−-SK-Hep1; Supplementary Fig. 7) and
CD147−/− HepG2 cell line (CD147−/−-HepG2; Supplementary
Fig. 7). The CD147−/−-HepG2 and CD147−/−-SK-Hep1 cells
were not recognized by CD147-CAR-NK-92MI cells (Fig. 1h–k),
which was quantified by CD107a surface expression when
cocultured with CD147−/− cell lines. Thus, we concluded that
only CD147+ HCC cell lines could selectively activate the CD147-
CAR-NK-92MI cells.
CD147-CAR-modified cells specifically kill HCC in vitro. Both
CD107a assay and cytokine production assay can be used to
evaluate the activation of CD147-CAR-NK-92MI cells by the
susceptible target cells. To directly test whether CD147-CAR-
modified immune cells can kill CD147+ HCC cells in vitro, we
used the 4-h Chromium-51 (51Cr) release assay, a gold standard
assay for evaluating the cytotoxicity of CTLs and NK cells in the
field of immunology, in combination with an FFLuc reporter
assay. The FFLuc reporter assay is a non-radioactive approach for
the assessment of CD147-CAR-modified immune cell cytotoxicity
using a luciferase bioluminescent signal.
CD147-CAR-modified primary T and NK cells isolated from
human PBMCs can kill multiple HCC cell lines (including SK-
Hep1, Huh7, and HepG2, etc.), but not κ-CAR-modified T cells
(Fig. 2a–c), by FFLuc reporter assays. We also demonstrated that
CD147-CAR-modified human primary NK cells effectively killed
HCC cell lines in vitro, by 51Cr release assay (Fig. 2d–f). To
further demonstrate that the natural killing ability of primary NK
through the NKG2D and NKG2D-Ligand (NKG2D-L) interac-
tion in addition to CD147-CAR primary NK cytotoxicity,
we observed that anti-NKG2D further blocked the killing of
CD147−/−-SK-Hep1 cells by CD147-CAR-NK (Fig. 2g).
The dose-dependent specific lysis of SK-Hep1 (Fig. 2i) using
the FFLuc reporter assay is comparable with 51Cr release assays
(Fig. 2h). The cytotoxicity by these two complementary
approaches was further directly quantified under a common
inverted fluorescence microscope to evaluate the morphology and
dynamics of GFP signal in target cells (Supplementary Fig. 8 and
Supplementary Movie 1). Together, these complementary
approaches demonstrate that CD147-CAR-NK cells specifically
kill CD147+ HCC in vitro.
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Expectedly, CD147-CAR-NK-92MI cells could not kill
CD147−/−-SK-Hep1, and CD147−/−-HepG2 cells, compared
to parental SK-Hep1 and HepG2 cells (Fig. 2k, d, l). In
addition, anti-CD147 antibody (clone HIM6) blocked the
specificity of CD147-CAR-NK-92MI cell cytotoxicity (Fig. 2m,
n). To further validate CD147 as an effective and valid target
for HCC, we examined the cytotoxicity of CD147-CAR-T cells
against two different HCC cell lines—HepG2 (Supplementary
Fig. 9A) and SK-Hep1 (Supplementary Fig. 9B), using the
FFLuc reporter assays.
Expectedly, when cocultured with CD147−/−-SK-Hep1 target
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Fig. 1 Activation profiles of CD147-CAR-NK-92MI stimulated with sensitive target cells. a Representative flow cytometric data illustrating CD107a
degranulation by NK-92MI, CD19-4-1BB-CAR, CD19-CD28-CAR, and CD147-CAR after mixing with the medium (control), SK-Hep1, and HepG2.
b Quantitative data for the percentage of surface CD107a expression on CD147-CAR-NK-92MI cells upon different stimulations, as indicated. Data
represent the mean ± SEM (n= 4). c, d Cytokine TNF-α (c) and IFNγ (d) production by CD147-CAR-NK-92MI, CD19-4-1BB-CAR-NK-92MI, CD19-CD28-
CAR-NK-92MI, and wild-type NK-92MI stimulated by different conditions. Data are pooled from four independent experiments. e Representative data
showing the percentage of surface CD107a expression on CD147-CAR-NK-92MI cells upon different stimulations, as indicated. Isotype-mouse IgG (IgG) or
PBS (vehicle control group) was used, as indicated. f, g Quantitative data for the percentage of surface CD107a staining on CD147-CAR-NK-92MI cells
stimulated with CD147+ SK-Hep1 and CD147+ HepG2 cell lines. Wild-type NK-92MI cells alone and CD147-CAR-NK-92MI cells alone were used as
controls, as indicated. Data represent the mean ± SEM of four independent experiments. h Representative data showing the percentage of surface CD107a
expression on CD147-CAR-NK-92MI cells stimulated with CD147+ wild-type (WT) SK-Hep1 cell line (top panel) and CD147-knockout (CD147−/−) SK-
Hep1 cell line (middle panel). i Quantitative data for the percentage of surface CD107a staining on CD147-CAR-NK-92MI cells stimulated with CD147+ SK-
Hep1 (WT) and CD147-knockout SK-Hep1 (CD147−/−) cell lines, respectively. Data represent the mean ± SEM of three independent experiments.
j Representative data showing the percentage of surface CD107a expression on CD147-CAR-NK-92MI cells stimulated with a CD147+ wild-type (WT)
HepG2 cell line (top panel) and a CD147-knockout HepG2 cell line (middle panel). k Quantitative data for the percentage of surface CD107a staining on
CD147-CAR-NK-92MI cells stimulated with CD147+ HepG2 (WT) and CD147-knockout HepG2 (CD147−/−) cell lines, respectively. Data represent the
mean ± SEM of three separate experiments. Unpaired Student’s t test was employed for all the panels. ***p < 0.001; n.s. not significant.
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decreased (Supplementary Fig. 9C), which further validated the
specific cytotoxicity of CD147-CAR-T cells against CD147+ HCC
cell lines. Together, the data indicate that CD147-CAR-modified
immune cells, including primary T and NK cells, as well as NK-
92MI cells, can kill CD147+ target cells, selectively and
specifically.
CD147-CAR-modified cells control HCC growth in vivo. To
evaluate whether CD147-CAR can kill HCC in vivo, two different
xenograft models were used. First, CD147-CAR-modified pri-
mary T and NK cells derived from PBMCs were evaluated in an
SK-Hep1 xenograft mouse model (Fig. 3). CD147-CAR-modified
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survival (Fig. 3a–d). To further evaluate the efficacy of CD147-
CAR-modified primary NK cells, we included a non-transduced
(NT) primary NK group as an additional control group
(Fig. 3e–h). Expectedly, mice treated with parental NT-NK or
phosphate-buffered saline (PBS) vehicle developed rapid disease
progression (Fig. 3). In contrast, mice treated with CD147-CAR-
modified primary T and NK cells were significantly protected
from rapid disease progression and their median survival was
prolonged (P < 0.05), with comparable body weights among all
groups (Fig. 3c–g), indicating the tolerable toxicity of CD147-
CAR-modified primary T and NK cells in vivo.
Furthermore, to further develop additional “off-the-shelf” cell
therapy strategies, we evaluated the efficacy of CD147-CAR-NK-
92MI cells. Due to the malignant nature of NK-92MI, CAR-NK-
92MI cells need to be irradiated before being administered to
patients47,63. We compared the cytotoxicity of non-irradiated and
irradiated CD147-CAR-NK-92MI cells by standard 4-h 51Cr
release assays (Supplementary Fig. 10). Comparable cytotoxicity
between non-irradiated and irradiated CD147-CAR-NK-92MI
cells was observed in vitro (Supplementary Fig. 10). We further
compared the efficacies between non-irradiated and irradiated
CD147-CAR-NK-92MI cells in the xenograft NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mouse model (Supplementary Fig. 11).
Comparable in vivo efficacies measured by median survival
between non-irradiated and irradiated CD147-CAR-NK-92MI-
infused mice were observed (Supplementary Fig. 11).
To further evaluate the efficacy of CD147-CAR-NK-92MI cells
(injected on days 1, 3, and 5 after tumor implantation) to control
tumor growth, disease progression was determined by measuring
tumor size (Fig. 4a). Expectedly, mice treated with parental NK-
92MI and PBS vehicle control groups developed rapid disease
progression (Fig. 4b). In contrast, mice treated with CD147-CAR-
NK-92MI cells were significantly protected from rapid disease
progression and their median survival was prolonged (P < 0.01),
with comparable body weights among the different groups
(Fig. 4c, d), indicating the tolerable toxicity of CD147-CAR-
NK-92MI cells in vivo.
Although cancer cell lines may have significant limitations in
their ability to precisely model biology and therapeutic effects64,
patient-derived xenografts65 (PDXs) models are biologically
stable and can mimic human clinic conditions regarding
mutational status, gene expression patterns, and tumor hetero-
geneity. Thus, we employed another xenograft mouse model
using metastatic liver cancer tissue from a patient. We tested the
ability of CD147-CAR-NK-92MI cells administered on days 0, 4,
8, 11, 15, 22, 25, and 35 after engraftment. The median survival of
mice treated with non-irradiated CD147-CAR-NK-92MI cells
was 63 days, which was significantly higher than that of control
mice, which was ~42 days. Reduced tumor burden and disease
progression were observed in the mice treated with CD147-CAR-
NK-92MI cells (Fig. 4e–h), indicating the effectiveness of CD147-
CAR-NK-92MI cells in suppressing liver cancer progression in
our PDX mouse model.
HCC-derived CD147-CAR-NK cells kill an CD147+ HCC cell
line. Due to CD147’s broad expression pattern across multiple
solid tumor types, CD147 is an attractive target for CD147-CAR-
based cancer immunotherapy. In addition to the previous stu-
dies37, we further examined whether CD147 is upregulated in
human HCC tissue samples. Different stages of HCC tumor tissue
stained strongly positive for CD147, compared to healthy liver
tissue (Fig. 5a).
To evaluate whether CD147-CAR-modified primary NK cells
directly isolated from HCC-affected livers can kill HCC in vitro,
we isolated NK cells from different zones of HCC liver tissue
(Fig. 5b), which included a tumor zone, tumor adjacent zone, and
a non-tumor zone. Then, we expanded these NK cells (Fig. 5c)
and generated CD147-CAR-NK cells using these expanded
primary NK cells directly isolated from HCC liver tissues. The
transduction efficiency of activated NK cells was generally >70%
(Fig. 5d). The anti-tumor activity of CD147-CAR-NK was
evaluated against HCC cell lines (Fig. 5e). Together, we conclude
that CD147-CAR-redirected primary human liver NK cells kill
the CD147+ target cells, selectively and specifically.
LogCD147-CAR-T cells kill only CD147+GPC3high HCC cells.
To mitigate off-tumor toxicity to NT, we assessed how the density
of CD147 expression in different types of cells, with a focus on
hematopoietic cells, affects the anti-tumor activity of CD147-
CAR. We first examined CD147 expression among HepG2, Raji,
Daudi, and PBMCs and observed different expression profiles
(Supplementary Fig. 12a). Notably, those cells (e.g., PBMCs)
expressing low levels of CD147 did not trigger cytotoxicity
activity of CD147-CAR-NK-92MI cells even at the high effector
and target ratio (E:T ratio) of 10:1 (Supplementary Fig. 12b).
These findings suggest that the optimized scFv sequence of anti-
CD147 only allows the specific scFv domain to bind with high-
expressing CD147, which can mitigate off-tumor toxicity towards
NTs that express low levels of CD147.
To further mitigate off-tumor toxicity of CD147-CAR, we used
a synNotch receptor that can release transcription factors, which
in turn drives expression of a CAR against a different tumor
antigen66. This “logic-gated” synNotch CAR can only kill dual
Fig. 2 CD147-CAR-T and CD147-CAR-NK cells specifically kill CD147+ tumor cells in vitro. a Specific cytotoxicity of primary CD147-CAR-T cells was
measured by FFLuc reporter assays, compared to κ-CAR-T cells (control group). Data represent the mean ± SEM (n= 6). b, c Significantly decreased
cytotoxicity of CD147-CAR-T cells using knockout-CD147 FFLuc-GFP-SK-Hep1 cell line and HepG2 cell line by FFLuc reporter assays. Data represent the
mean ± SEM from three independent experiments. d Cytotoxicity of primary CD147-CAR-NK cells was measured by the 4-h standard 51Cr release assays,
compared to κ-CAR-T cells (control group). Data represent the mean ± SEM (n= 6). e, f Significantly decreased cytotoxicity of primary CD147-CAR-NK
cells using knockout-CD147 FFLuc-GFP-SK-Hep1 cell line and HepG2 cell line by the 4-h standard 51Cr release assays. Data represent the mean ± SEM from
three independent experiments. g Anti-NKG2D antibody blocks primary CD147-CAR-NK naturally killing to FFLuc-GFP-SK-Hep1. Data represent the mean
± SEM from three independent experiments. h Cytotoxicity of CD147-CAR-NK-92MI to the SK-Hep1 was measured by a standard 4-h 51Cr release assay.
Data represent the mean ± SEM (n= 6). i, j FFLuc reporter system assay for specific killing of FFLuc-GFP-SK-Hep1 and FFLuc-GFP-HepG2 cell lines by
CD147-CAR-NK-92MI. Effector cells (CD147-CAR-NK-92MI and NK-92MI) were cocultured with 1 × 104 FFLuc-GFP-SK-Hep1 (i) or FFLuc-GFP-HepG2 (j)
target cells per well in a 96-well optical-bottom microplate for 6 h. The control groups (blue) used were wild-type NK-92MI incubated with CD147+ FFLuc-
GFP-SK-Hep1 or CD147+ FFLuc-GFP-HepG2. Data represent the mean ± SEM (n= 6). k, l Decreased cytotoxicity of CD147-CAR-NK-92MI cells using
knockout-CD147 FFLuc-GFP-SK-Hep1 (k) and knockout-CD147-FFLuc-GFP-HepG2 (l) cell lines by FFLuc reporter system assay. Data represent the mean ±
SEM (n= 3, 6 for SK-Hep1 and HepG2 groups, respectively). m, n Anti-CD147 (clone, HIM6) inhibits the CD147-CAR-NK-92MI-specific lysis effect against
and FFLuc-GFP-SK-Hep1 (m) and FFLuc-GFP-HepG2 (n). Data represent the mean ± SEM from three independent experiments. Two-tailed unpaired
Student’s t test was employed for all the panels. ***p < 0.001; n.s. not significant.
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antigen-positive tumor cells, but not single tumor antigen-
positive tumor cells (Fig. 6a, b).
Further, we designed a combination approach consisting of
GPC3 and CD147 to mitigate off-tumor toxicity. Briefly, we
constructed an SFG retroviral vector encoding an anti-GPC3-
specific synNotch receptor linking a Gal4VP64 intracellular
transcription activation domain. A constitutively expressed
enhanced GFP (eGFP) was placed downstream of the GPC3-
synNotch to identify transduced cells (Fig. 6a).
A lentiviral vector was constructed in which the anti-CD147-
CAR was placed under control of the upstream activating
sequence promoter that can be activated by Gal4VP64 transcrip-
tion factors released after engagement of the synNotch receptor66.
A constitutively expressed monomeric read fluorescent protein
Cherry (mCherry) was placed downstream of the inducible
CD147-CAR to identify transduced cells (Fig. 6a).
Human PBMCs were cotransduced with both lentiviral and
retroviral vectors (Fig. 6c). The double-positive cells were verified
by eGFP (a marker for anti-GPC3-synNotch) and mCherry (a
marker for CD147-CAR) using flow cytometry analysis (Fig. 6d).
Four subsets of transduced T cells (including mCherry+-only,
GFP+-only, GFP- and mCherry-double-positive, and GFP- and
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mCherry-double-negative subsets) were analyzed (Fig. 6e). These
transduced T cells were primed by a GPC3highCD147−/−-HepG2
to induce CD147-CAR expression on the surface (Fig. 6f).
Expectedly, we did not observe a leakiness of CAR expression in
transduced primary T cells in the absence of synNotch signaling.
This observation was further verified by a gamma secretase
inhibitor (MK-0752, Notch signaling inhibitor) treatment assay
(Supplementary Fig. 13). The CD147-CAR expression on GPC3-
synNotch-GFP- and CD147-CAR-mCherry-double-positive
T cells was dramatically inhibited upon MK-0752 treatment
(Supplementary Fig. 13).
Following GPC3-synNotch-GFP and CD147-CAR-mCherry
cotransduction of T cells and primed by the CD147koGPC3high-
HepG2, the cytotoxic activities of transduced T cells were
triggered by different subsets of HCC cell lines for 2 h to assess
specific tumor-killing efficacy. The different subsets of HCC cell
lines were: CD147+GPC3high HepG2, CD147koGPC3high HepG2,
CD147+GPC3low HepG2, and CD147koGPC3low HepG2 (Fig. 6g).
Phorbol-12-myristate-13-acetate/ionomycin was used as a posi-
tive control.
GPC3-synNotch-GFP- and CD147-CAR-mCherry-double-
positive T cells that were primed with CD147koGPC3high HepG2
cells can be specifically activated by the CD147+GPC3high HepG2
cells (Fig. 6h), which was quantified by CD107a surface
expression when cocultured with different target cell lines.
Similar results were obtained when we cotransduced a myc-
tagged CD147-specific-synNotch-GFP and inducible GPC3-
CAR-mCherry into T cells (Supplementary Fig. 14).
Together, the data suggest that GPC3-synNotch-inducible
CD147-CAR-T cells can specifically be activated by only CD147+
GPC3high HepG2 cells, but not by CD147koGPC3+ or CD147+
GPC3low HepG2 cells. These activated CD147-CAR-T cells can
kill CD147+GPC3high HepG2 cells, but not CD147koGPC3+
HepG2 cells (Supplementary Fig. 15).
To further test whether the GPC3-synNotch-inducible CD147-
CAR cells can control progression of HCC in vivo, 1.3 × 106
irradiated GPC3-synNotch-inducible CD147-CAR-NK-92MI
cells with 2 × 104 IU IL-2 were adoptively transferred intraper-
itoneally (i.p.) into the CD147+GPC3high HepG2 and CD147+
GPC3low HepG2 inoculated xenograft NSG mice (Supplementary
Fig. 16). The CD147+GPC3low HepG2 cells cannot effectively
prime the GPC3-synNotch-inducible CD147-CAR-NK-92MI
cells due to the low surface expression of GPC3 molecules. As
expected, tumor burden from the CD147+GPC3high HepG2
inoculated mice treated with GPC3-synNotch-inducible CD147-
CAR-NK-92MI cells was reduced, compared with that of mice
bearing CD147+GPC3low HepG2 tumor cells (Supplementary
Fig. 16). These data reveal GPC3-synNotch-inducible CD147-
CAR-NK-92MI cells are potently cytotoxic and can control
progression of HCC in vivo.
Previous studies show that epithelial and fetal tissues under
normal conditions express low levels of CD147 molecule34.
CD147 is expressed on a variety of cell types (e.g., hemato-
poietic, epithelial, and endothelial cells) and at varying levels33.
To test whether the toxicity that may result from GPC3-
synNotch-inducible CD147-CAR targeting of CD147 in healthy
tissues, we generated a hCD147TG mouse model to test the on-
target/off-tumor toxicity of GPC3-synNotch-inducible CD147-
CAR-NK-92MI treatment of HCC (Supplementary Fig. 17).
Genotyping confirmed the successful generation of hCD147TG
(Supplementary Fig. 17A). IHC showed human CD147
(hCD147) expression on liver tissues on hCD147TG mice
(Supplementary Fig. 17B). The genotyping products were
verified by sequencing. To test whether the on-target/off-tumor
toxicity of GPC3-synNotch-inducible CD147-CAR-NK-92MI
cells, non-tumor-bearing hCD147TG mice were treated with
in vitro activated, primed, and irradiated GPC3-synNotch-
inducible CD147-CAR-NK-92MI cells. The body weight of
treated animal was recorded, as well as appearance and activity.
Notably, the body weight of treated animal slightly increased
after three doses of activated GPC3-synNotch-inducible
CD147-CAR-NK-92MI cell injection (Supplementary Fig. S18).
Thus, we conclude that these activated GPC3-synNotch-
inducible CD147-CAR-NK-92MI cells do not cause severe
on-target/off-tumor toxicity in vivo.
Discussion
We show that human primary T cells, primary NK cells, and
NK-92MI cell line transduced with CD147-CAR molecules can
specifically kill malignant HCC cell lines in vitro, and control
progression of HCC in a xenograft mouse model, a PDX mouse
model, and a hCD147TG mouse model. We also observed tran-
sient fratricide during CD147-CAR-NK-92MI expansion due to
the presence of a low CD147 expressing subset of parental NK-
92MI. However, the transient fratricide did not affect the cyto-
toxicity, expansion, and proliferation of CD147-CAR-NK-92MI
cells. Instead, this transient fratricide selected for the CD147− or
relatively lower expressing subset of CD147-CAR-NK-92MI and
facilitated its expansion. The synNotch receptor logic-gated
GPC3 and CD147-CAR can further mitigate on-target/off-
tumor toxicity to NT in a hCD147TG mouse model. These
findings support the clinical development of CD147-CAR for
HCC immunotherapy.
Fig. 3 Primary CD147-CAR-T and CD147-CAR-NK cells control progression of HCC in a xenograft mouse model. a Diagram of experimental design of
HCC xenograft model. Briefly, NSG mice were subcutaneous injected with SK-Hep1 cells premixed with equal volume Matrigel (day 0). Tumor burden was
determined by size, and once reaching nearly 50mm3, mice would be randomly grouped on day 4. At day 5 (D5), mice were injected (i.v.) with one dose of
1 × 107 effector CD147-CAR-T (group #1) cells with IL-2. At days 7, 9, and 16, identical treatments in each group were administered. Day 0 was defined as
the initial tumor cell injection time point. b Quantification of tumor burden of SK-Hep1 xenografts treated with CD147-CAR-T and PBS, respectively. All
results are mean ± SEM. The difference for each group was analyzed by two-way ANOVA analysis. c Body weights of each group were measured at the
indicated time points. d Kaplan–Meier survival curves of tumor-bearing mice after treatment with CD147-CAR-T cells and PBS. The p value was analyzed
by log-rank (Mantel–Cox) test. b–d n= 10 mice per group. e Diagram of experimental design for anti-tumor efficacy of primary CD147-CAR-NK in HCC
xenograft model. After tumor implantation for 5 days (day 5), the mice were injected (i.v.) with one dose 1 × 107 effector primary CD147-CAR-NK cells with
IL-2. The control groups were injected with the same number of non-transduced primary NK cells with IL-2 or PBS only. At days 5, 7, 9, 16, and 18, identical
treatments in each group were administered, as indicated. f Quantitative tumor burden of HCC xenograft mice treated with primary CD147-CAR-NK, non-
transduced primary NK, and PBS, respectively. All results are mean ± SEM. The difference for each group was analyzed by two-way ANOVA analysis.
g Body weights of each group were measured at the indicated time points, and analyzed by two-way ANOVA analysis. h Kaplan–Meier survival curves of
tumor-bearing mice after treatment with primary CD147-CAR-NK, parental primary NK groups, and PBS. The difference for each group was analyzed by
log-rank (Mantel–Cox) test. Data represent two separate experiments. The p values are indicated as in comparison of the CD147-CAR-modified cells
treated groups with the control groups. f–h n= 11 mice per group; n.s. not significant.
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Recently, an agent against CD147, called ABX-CBL (gavili-
momab, a hybridoma-generated murine IgM monoclonal anti-
body), has been proposed to specifically inhibit graft rejection
after CD147 blockade was tested for the treatment of steroid-
resistant acute GVHD67.
Metuzumab (a recombinant, glycoengineered human/mouse
chimeric IgG1 monoclonal antibody against the extracellular C2
domain of hCD147, HAb18G) was developed to optimize
antibody-dependent cellular cytotoxicity68. A 131I-labeled HAb18
F(ab′)2 (Licartin) targeting CD147 has been reported as an effi-
cacious and safe treatment option for patients with primary
HCC45.
However, current antibody-based immunotherapy strategies
lack a sustained effect, given the short half-life of IgM antibody
(~5–6 days) and of IgG1 (~21 days). The second disadvantage of
using an antibody is the development of human anti-mouse
antibodies, which limits the application of murine antibodies in
clinical contexts.
CD147-CAR-T cells or NK cells have better longevity and the
additional benefit of self-replication. Some CAR-T cells exhibit
long-lived, memory-like phenotypes and reside in the bone
marrow for more than several years69–71,72. Manageable toxicities





D0 D2 D4 D6 D9 D13
D1 D3 D5
.......
Group #1. CD147-CAR n = 8
Group #2. NK-92MI n = 6




























































































D0 D4 D8 D11D15 D22
D1 D6 D10
.......
Group #1. CD147-CAR n = 7
Group #2. NK-92MI n = 6
Group #3. Vehicle n = 4

























































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18444-2 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:4810 | https://doi.org/10.1038/s41467-020-18444-2 | www.nature.com/naturecommunications 9
Successful manufacture and time-sensitive infusion of auto-
logous CAR-modified immune cells is the key to an effective
CAR-T or CAR-NK cell-based immunotherapy47. However, it is
challenging to produce CAR-T or CAR-NK cells from patients
with high-risk solid tumors73. Therefore, the CD147-CAR-NK
cells developed here may provide an allogeneic off-the-shelf cell-
based product. A pressing issue existing in the field of immu-
notherapy is uncertainty around whether an off-the-shelf
universal CAR product can be developed47. CAR-T cell pro-
ducts from individuals are costly and take a considerable
amount of time to prepare. Generation of off-the-shelf CAR-T or
NK cell products will significantly reduce the cost of immu-
notherapy. Using clustered regularly interspaced short palin-
dromic repeats (CRISPR) and the CRISPR-associated protein 9
(Cas9) technique74, as well as other gene-editing technologies to
knockout endogenous TCR’s and HLA class I molecules for
universal CAR-modified T cell generation are still in preclinical
phases47,75. Unfortunately, most of these strategies are still in the
early phase.
Compared to other CAR-T cell immunotherapy for HCC, the
proposed CD147-CAR-modified immune cells possess three
distinct advantages. First, we identified that the CD147 molecule
can be used as an effective and valid target for CAR-mediated
immunotherapy in vitro and in vivo. Second, CD147-CAR-NK-
92MI is feasible with high specificity and tolerable toxicity. Third,
CD147-CAR-NK cells have a potential for off-the-shelf products
for various tumors with CD147 upregulation.
Since CD147 is also expressed on several organs with varying
expression levels, there is a concern that infused CD147-CAR-
modified immune cells may also target other organs. Therefore,
such on-target/off-tumor toxicity should be tested in future clin-
ical trials. Our data show that GPC3-synNotch-inducible CD147-
CAR-T cells or CD147-synNotch-inducible GPC3-CAR-T or
GPC3-CAR-NK cells can be specifically activated by CD147+
GPC3high HepG2 cells, but not CD147koGPC3+ or CD147+
GPC3low HepG2 cells. Meanwhile, this on-target/off-tumor
toxicity of CD147-CAR-NK or CD147-CAR-T cell therapy may
be manageable by introducing suicide genes76, using messenger
RNA transfection77, a split, universal, and programmable CAR
system78, intratumoral injections of CAR-modified cells79, or a
synNotch CAR design80–82.
In conclusion, we demonstrate that CD147-CAR can effectively
redirect human immune cells (primary T, primary NK, and NK-
92MI cells) to target malignant HCC cells with limited fratricide
in vitro and in vivo. Meanwhile, the hCD147TG mouse model
developed in this study will be useful in testing hCD147-CAR cell
safety. This approach may provide treatment options for patients
with HCC. Importantly, future clinical trials using CD147-CAR,
as well as transgenic animal models, will further evaluate the on-
target/off-tumor toxicity.
Methods
Antibodies and reagents. Purified anti-CD247 (also known as T cell surface
glycoprotein CD3ζ) antibody (clone 6B10.2, BioLegend), purified anti-hCD147,
fluorescein isothiocyanate (FITC)-conjugated anti-hCD147 (clone HIM6, BioLe-
gend), phycoerythrin (PE)- or allophycocyanin (APC)-conjugated anti-human
CD3 antibody (clone OKT3, BioLegend), FITC- or BV510-conjugated anti-human
CD56 antibody (clone HCD56, BioLegend), PE-conjugated anti-human CD69
antibody (clone FN50, BioLegend), APC/Fire 750-conjugated anti-human CD226
antibody (also known as DNAM-1, clone 11A8, BioLegend), APC/Fire 750-
conjugated anti-human KLRG1 (MAFA) antibody (clone SA231A2, BioLegend),
BV421-conjugated anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend),
PE/Cy7-conjugated anti-human CD158b (KIR2DL2/L3, BioLegend) antibody
(clone DX27, BioLegend), PE/Cy7-conjugated anti-human CD244 (2B4) antibody
(clone C1.7, BioLegend), PE-conjugated anti-human CD152 (CTLA-4) antibody
(clone BNI3), APC-conjugated anti-human CD366 (Tim-3) antibody (clone F38-
2E2), PerCP/Cy5.5 anti-human TIGIT (VSTM3) antibody (clone A15153G), FITC-
conjugated anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend),
and PerCP/Cy5.5-conjugated anti-human CD94 (clone DX22, BioLegend) were
purchased from BioLegend (San Diego, CA, USA).
APC-conjugated anti-human CD16 antibody (clone B73.1, BD Biosciences),
FITC-conjugated anti-human CD3 antibody (clone UCHT1, BD Biosciences),
BV480-conjugated anti-human CD85j antibody (LIR-1) antibody (clone GHI/75,
BD Biosciences), BV711-conjugated anti-human CD314 (NKG2D) antibody (clone
1D11, BD Biosciences), and PE- or FITC-conjugated anti-human CD107a antibody
(clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose,
CA, USA).
FITC-conjugated anti-human KIR/CD158 antibody (clone 180704, R&D
Systems), PE-conjugated anti-human KIR2DL1/KIR2DS5 antibody (clone 143211,
R&D Systems), APC-conjugated anti-human KIR3DL1 antibody (clone DX9, R&D
Systems), AF405-conjugated anti-human KIR3DL2/CD158k antibody (clone
539304, R&D Systems), APC-conjugated anti-human NKG2A/CD159a antibody
(clone 131411, R&D Systems), and PE-conjugated anti-human NKG2C/CD159c
antibody (clone 134591, R&D Systems) were purchased from R&D Systems. AF647
Goat anti-human IgG F(ab′)2 fragment antibody was purchased from Jackson
ImmunoResearch (West Grove, PA, USA). All primary antibodies used for flow
cytometry were used at the same final concentration (1:100 dilution), unless
otherwise specified. For immunofluorescence assays, the concentrations of primary
and secondary antibodies were 1:100 and 1:1000 dilutions, respectively.
Bioinformatic analysis from public cancer patient database. Patient survival
data and RSEM (RNA-sequencing by expectation maximization) normalized
expression datasets about CD147 were generated from TCGA and were down-
loaded from OncoLnc (http://www.oncolnc.org/). Data were plotted for
Kaplan–Meier curves using GraphPad Prism 5.0 (GraphPad). RSEM normalized
expression datasets derived from TCGA come from FireHose Broad GDAC, which
was developed by The Broad Institute (https://gdac.broadinstitute.org/). Figures
also were generated by GraphPad Prism 5.0.
Cell lines. NK-92, NK-92MI, 293T, K562, Daudi cell, SK-Hep1, and HepG2 cell
lines were purchased from American Type Culture Collection (ATCC). T2 cell line
was a gift from Dr. June Kan-Mitchell (University of Texas at EI Paso, EI Paso,
TX). MDA-MB-231 was a gift from Dr. Mien-Chie Hung (University of Texas MD
Anderson Cancer Center, Houston, TX). The 721.221 cell line was a gift from Dr.
Eric O. Long (National Institute of Allergy and Infectious Diseases, NIH). To
Fig. 4 Non-irradiated CD147-CAR-NK-92MI cells control progression of HCC in a xenograft mouse model and a PDX mouse model. a Diagram of
experimental design of HCC xenograft model. At day 0, tumor burden (~50mm3) was determined and mice were randomly grouped. Of note, day 0 was
defined as the day before CAR treatment. b Quantification of tumor burden of SK-Hep1 xenografts treated with CD147-CAR-NK-92MI, parental NK-92MI
cells, and PBS, respectively. All results are mean ± SEM. The difference for each group (n= 6–8 per group) was analyzed by two-way ANOVA analysis.
*P < 0.05, **p < 0.01, and *** p < 0.001 are indicated as in comparison of the CD147-CAR-treated group with the NK-92MI-treated group. +P < 0.05, ++p <
0.01, and +++p < 0.001 are indicated in comparison of the CD147-CAR-treated group with the vehicle control-treated group. c Body weights of each group
were measured at the indicated time points. d Kaplan–Meier survival curves of tumor-bearing mice after treatment with CD147-CAR-NK-92MI cells (n=
8), parental NK-92MI group (n= 6), and PBS (n= 7). e Diagram of experimental design for anti-tumor efficacy of CD147-CAR-NK-92MI in a liver PDX
model. After tumor implantation for 4 weeks (day 1), tumor burden was determined (~50mm3) and mice were randomly grouped. f Quantitative tumor
burden of PDX mice treated with CD147-CAR-NK-92MI cells, parental NK-92MI cells (control group), and PBS (vehicle control group), respectively. All
results are mean ± SEM. The difference for each group was analyzed by two-way ANOVA analysis. *P < 0.05, **p < 0.01, and ***p < 0.001 are indicated as
in comparison of the CD147-CAR-treated group with the NK-92MI-treated group. The ++p < 0.01, and +++p < 0.001 are indicated in comparison of the
CD147-CAR-treated group with the vehicle control-treated group. g Body weights of each group were measured at the indicated time points. h
Kaplan–Meier survival curves of tumor-bearing mice after treatment with CD147-CAR-NK-92MI cells (n= 7), parental NK-92MI groups (n= 6), and PBS
(n= 4). The p value analysis by log-rank (Mantel–Cox) test. Data are from two experiments.
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establish the FFluc-GFP+, CD147+ HepG2, and SK-Hep1 cells were transduced
with a lentiviral vector encoding FFLuc-GFP. The GFP+ cells were sorted by BD
FACS Aria III. The protocol for collection of peripheral blood from healthy donors
and liver tissue from HCC patients were approved by the institutional review board
(IRB) and ethics review committees at the Rutgers-New Jersey Medical School
(Newark, NJ). Where necessary, patient consent was obtained before obtaining
clinical samples.
HCC tumor and liver-derived CAR-NK cell culture and generation. A patient
scheduled for an orthotopic liver transplant at the University Hospital was selected
as a suitable candidate for the purposes of generating primary liver CAR-NK cells
under the approved IRB protocols. The recipient’s liver tissues were analyzed at the
department of pathology, immunology, and laboratory medicine in Rutgers-New
Jersey Medical School. Sample tissues from the grossed tumor, adjacent, and dis-
tant unaffected areas were harvested. After briefly mincing the tissue using sterile
forceps, the tissue was further dissociated using a GentleMACS Octo with heater
(Miltenyi Biotec) for 45 min in collagenase IV (Thermo Fisher) using a custom
dissociation protocol. Next, the resulting suspension was triturated through a 70
µm cell strainer (Corning) before washing with 30% Percoll (GE Healthcare) and
spinning at 400 × g for 5 min at room temperature. The supernatant was aspirated,
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Fig. 5 Patient-derived Primary CD147-CAR-NK cells specifically kill CD147+ tumor cells in vitro. a, b Representative H&E and IHC staining of liver
samples from different stages of one HCC patient. Scale bar, 200 µm. c Diagram of experimental design of HCC sample acquisition from different areas of
liver cancer tissues. Briefly, three regions of interest (tumor zone, adjacent zone, and non-tumor zone) were obtained. Primary NK cells were isolated from
these zones, indicated by different colors. Scale bar, 2 cm. d Flow cytometry analysis of CD147-CAR+ primary NK cells from different zones of liver tissues.
e Cytotoxicity of primary CD147-CAR-NK cells was measured by 4-h standard Cr51 release assays. All results are mean ± SEM. Data are from at least two
experiments.
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over Lymphocyte Isolation medium (Corning) for density gradient centrifugation
at 400 × g for 23 min without acceleration or brakes. The Ficoll layer was carefully
collected and washed with complete medium before putting into culture to expand
liver-resident NK cells. The protocol for collection of liver tissue from HCC
patients was approved by the Rutgers IRB and ethics review committees at Rutgers-
New Jersey Medical School (Newark, NJ). Where necessary, patient consent was
obtained before obtaining clinical samples. NK and CAR-NK cells were expanded
with 100-Gy irradiated 721.221-mIL21 cells and supplemented with 200 U/mL IL-2
and 5 ng/mL IL-15 (Peprotech, Rocky Hill, CT, USA)83.
NK-92MI cell culture and generation of CAR-modified NK-92MI cells. NK-
92MI cell line was purchased from ATCC (CRL-2408, USA). NK-92MI, an IL-2-
independent NK cell line, is derived from NK-92 (ATCC CRL-2407) cell line49
stably expressed with human IL-2 cDNA59,62. NK-92MI cells were maintained in
the specific NK-92MI culture medium (α-minimum essential medium) without
ribonucleosides or deoxyribonucleosides, but with 2 mM L-glutamine and 1.5 g/L
sodium bicarbonate. To make the complete growth medium, the following com-
ponents were added to the base medium: 0.2 mM inositol, 0.1 mM 2-mercap-
toethanol, 0.02 mM folic acid, horse serum to a final concentration of 12.5%, and
fetal bovine serum (FBS) to a final concentration of 12.5%. NK-92MI cells were
transduced with retroviral supernatants on day 3 in plates coated with recombinant
fibronectin fragment (RetroNectin; Takara, Japan). After transduction, NK cells
were maintained using minimal concentration IL-2 (40 ng/mL). To check the
percentage of CD147-CAR expression on NK-92MI cells, these cells were stained
for CD3 and CD56 to stain NK cells, followed by flow cytometry analysis.
Generation of CD147−/− cell line. To generate the CD147−/− HCC cell lines, we
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Fig. 6 GPC3-synNotch-inducible CD147-CAR-T cells selectively target GPC3+CD147+-double-positive, but not single-positive HepG2 cells.
a Schematic design of GPC3-Gal4VP64-synNotch receptor in SFG retroviral vector and CD147-CAR based on the pHR lentiviral vector. The SFG retroviral
vector contains eGFP, which can be used as a marker for selecting GPC3-Gal4VP64-synNotch+ cells. The pHR lentiviral vector contains mCherry, which
can be used as a marker for selecting CD147-CAR+ cells. b Schematic design of “logic-gated” GPC3-synNotch and CD147-CAR showing induced
cytotoxicity when both antigens are coexpressed, but not when they are separately expressed on bystander or healthy cells. c, d Schematic experimental
design of GPC3-synNotch-GFP and CD147-CAR-mCherry vectors cotransduced T cells (c) and representative flow cytometric analysis of GPC3-synNotch-
GFP and CD147-CAR-mCherry expression (d). e Schematic experimental design of GPC3-synNotch-GFP and CD147-CAR-mCherry vectors cotransduced
into T cells, priming by GPC3highCD147low HepG2 cell line, and followed by CD147-CAR expression analysis among different subsets of transduced T cells,
including mCherry+-only, GFP+-only, GFP- and mCherry-double-positive, and GFP- and mCherry-double-negative subsets. f Representative flow
cytometric analysis of CD147-CAR expression on the surface of different subsets of transduced T cells. Both mean fluorescence intensity (MFI) and
percentage of CD147-CAR are displayed in each representative flow cytometric chart. g Representative flow cytometric analysis of CD147 and GPC3
expression on HepG2 tumor cell lines. h Quantitative analysis of surface CD107a expression on different subsets of transduced T cells after “primed and
triggered” protocol by different HepG2 tumor cell lines for 2 h. Data are representative of two independent experiments.
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CD147 sequence: #1 (5-TTGACATCGTTGGCCACCGC-3) and #3 (5-
GTGGACGCAGATGACCGCTC-3). Lentivirus was produced in HEK 293T by
transfecting Lenti-CRISPR v2 with packaging plasmids pSPAX2 and pMD2G.
After 3 days, supernatants were filtered (0.45 μm) and incubated with HCC cells
and 8 μg/mL polybrene (Sigma). After 48 h of incubation, transduced cells were
changed to a fresh medium and selected with 8.0 μg/mL puromycin for 5 days. WB
and flow cytometry analysis were performed to confirm the phenotype of the
knockout cell lines.
Plasmid construction and retrovirus production. A codon-optimized DNA
fragment was synthesized by GENEWIZ encoding the CD147-specific scFv from
the murine 5F6 clone and subcloned into the SFG retroviral vector retroviral
backbone in-frame with the hinge component of human IgG1, CD28 transmem-
brane domain, intracellular domain CD28 plus 4-1BB, and the ζ chain of the
human TCR/CD3 complex. To produce CD147-CAR retrovirus, 293T cells were
transfected with a combination of plasmids containing CD147-CAR, RDF, and
PegPam3, as previously described60. The construct of CD19-CD28-CAR and
CD19-4-1BB-CAR has been previously described61.
To generate the anti-GPC3-synNotch-induced receptor vector, anti-GPC3
(mouse GC33 clone) scFv that can specifically bind with human GPC3 antigen was
synthesized by GENEWIZ. The sequence encoding a signal peptide and a myc-tag
at the N-terminal were fused with the synNotch-Gal4VP64-induced element
derived from (Addgene plasmid #79125) by overlap PCR. The fragments were
inserted into the SFG gamma retrovirus vector, which were digested by restriction
endonucleases NcoI and XhoI.
For construction of the anti-CD147-CAR-mCherry vector, the entire CD147-
CAR element was inserted into pHR_Gal4UAS_pGK_mCherry (Addgene plasmids
#79124), which was digested by restriction endonucleases MluI and NdeI. The
expression of the mCherry gene was under control of the pGK promoter, as
described previously66. In this strategy, eGFP- and mCherry-double-positive cells
were gated as synNotch CAR-modified cells for further analysis and functional
evaluation.
To generate the anti-CD147-synNotch-induced receptor vector, anti-CD147
scFv was fused with the synNotch-Gal4VP64-induced element derived from
pHR_PGK_antiCD19_synNotch_Gal4VP64 (Addgene plasmid #79125) by overlap
PCR. A myc-tag was added to the N-terminal. The fragments were inserted into the
SFG gamma retrovirus vector after the signal peptide, which were digested by
restriction endonucleases SalI and MluI.
For construction of the anti-GPC3-CAR-mCherry vector, the entire GPC3-
CAR element, which contains anti-GPC3 (mouse GC33 clone) scFv, was inserted
into pHR_Gal4UAS_pGK_mCherry (Addgene plasmid #79124), which was
digested by restriction endonucleases MluI and NdeI. Expression of the mCherry
gene was under control of the pGK promoter. In this strategy, myc-tagged and
mCherry-double-positive cells were gated as synNotch CAR-modified cells for
further analysis and functional evaluation. All constructs and primers are
summarized in Supplementary Table 1.
Transduction of primary NK cells with CD147-CAR. NK cells were harvested on
day 7 of expansion and transduced with CD147-CAR retrovirus in plates coated
with RetroNectin. Two days later, cells were transferred to G-Rex 6 multi-well cell
culture plates and maintained in 35 mL of complete NK culture media according to
ATCC with 200 U/mL IL-2 (PeproTech). The medium was changed every 3–4 days
and 2 × 107 cells were kept in each well for continued culture at each time. Total
cell numbers were counted using trypan blue exclusion. To check the percentage of
NK cells and the expression of CAR, cells were stained for CD3, CD56, and IgG F
(ab′)2, and analyzed by flow cytometry.
Flow cytometry. CAR-modified immune cells were stained with fluorescence-
conjugated antibodies in FACS staining buffer (PBS with 1% FBS) on ice for 30 min
on ice in the dark. Then, cells were washed with PBS, and analyzed on either a
FACS LSRII or an LSR Fortessa flow cytometer (BD). Photomultiplier tube voltages
were adjusted using the FACS Diva (BD) software and compensation values were
calculated before data collection. Flow data were then acquired using FACS Diva
(BD) and analyzed using FlowJo (Tree Star).
For flow cytometry single live cell sorting, sample cells were stained with
fluorescence-conjugated antibodies with (RPMI-1640 with 1% FBS) on ice for 30
min, washed with PBS twice, resuspended in completed culture medium, and
sorted by SORP BD FACS Aria III. After sorting, collection samples were washed
with prewarmed medium once, and cultured for use.
CAR-NK degranulation (CD107a) assay. CD107a degranulation assay was
described previously84,85. Briefly, CAR-NK cells (1 × 105) were incubated with
target cells in U-bottomed 96-well plates in complete NK-92MI culture media at
37 °C for 4 h, 10 h, or overnight in the presence of CD107a with GolgiStop (BD).
Then, cells were stained for CD3 and CD56 for 30 min on ice. The expression of
CD107a was analyzed by flow cytometry.
Cytokine release assays. The IFNγ and TNF-α cytokines secreted by CAR-NK
cells were measured by a commercial ELISA kit (Invitrogen-Thermo Fisher Sci-
entific) as per the manufacturer’s protocol.
51Cr release assay. To evaluate the cytotoxic activity of CAR-NK cell, the stan-
dard 4-h 51Cr release assay was used. Briefly, target cells were labeled with 51Cr at
37 °C for 2 h and then resuspended at 2 × 105/mL in NK-92MI culture medium
with 10% FBS without IL-2. Then, 2 × 104 target cells were incubated with serially
diluted CAR-NK cells at 37 °C for 4 h. After centrifugation, the supernatants were
collected and the released 51Cr was measured with a gamma counter (Wallac,
Turku, Finland). The cytotoxicity (as a percentage) was calculated as follows:
[(sample− spontaneous release)/(maximum release− spontaneous release)] × 100.
FFLuc reporter assay. To quantify the cytotoxicity of CAR-modified immune cells,
we also developed the FFLuc reporter system assay. Briefly, on day 1, target cells
were preseeded at 2 or 3 × 104 target cells/well (FFluc-GFP stably transduced cell)
onto an optical 96-well plate (Greiner Bio-One™ No.: 655098) in 100 μL/well of the
target cell’s full nutrition medium and incubated at 37 °C with 5% CO2, overnight.
The next day, serial dilutions of effector cell were prepared according to the effector
to target ratio and added into each well (100 μL/well). The reaction was incubated at
37 °C with 5% CO2 for 4 h and then the supernatant was gently discarded. One
hundred microliters of working concentration D-luciferin was added to each well
and incubated at 37 °C with 5% CO2 for 5 min, with the lights turned off. A
microplate reader (PerkinElmer, USA) was used to quantify the data. The data were
quantified by converting the obtained values to percentage of specific lysis by the
following equation: specific lysis percentage (%)= [1− (S− E)/(T−M)] × 100,
where S is the value of luminescence of the sample well, E is the value of lumi-
nescence of the effector cell well compared to the sample well, T is the mean value
of luminescence of target cell wells, and M is the mean value of luminescence of
blank medium wells.
Animal studies. All animal experiments have been approved by the Rutgers
Institutional Animal Care and Use Committee (IACUC, PROTO201800200). NSG
mice from The Jackson Laboratory (Bar Harbor, ME) were used for all, in vivo,
experiments. To establish an HCC cell line xenograft model, both male and female
NSG mice (8-week-old) were injected subcutaneously with 4 × 106 SK-Hep1 cells in
100 μL of PBS Corning® Matrigel® Matrix in the right flank. When the tumor
burden reached 40–50 mm3, mice were randomly allocated into three groups.
Beginning treatment on day 1, the mice were injected (intravenously (i.v.)) with
5 × 106 CD147-CAR-NK-92MI cells in 100 μL of PBS. Control groups were infused
with either parental NK-92MI or vehicle (PBS). The next day (day 2), all animals
were injected (i.v.) with IL-2 (20,000 U/mouse). Animal weight and tumor burden
were collected, twice a week. The tumor size was measured by a caliper and the
greatest longitudinal diameter (length) and the greatest transverse diameter (width)
were recorded. Tumor sizes based on caliper measurements were calculated by the
modified ellipsoidal formula. The tumor size was calculated as follows: tumor size
(mm3)=½ (length × width2). When the tumor burden was >2000 mm3 or the
animal’s weight reduced >20%, mice were euthanized according to Rutgers IACUC
guidelines. The animal survival data were recorded simultaneously.
For the PDX model, patient metastatic liver cancer animal models were
developed and obtained by The Jackson Laboratory. Briefly, fresh PDX specimens
were implanted subcutaneously into the flanks of 6–8-week-old NSG mice. After
the tumor burden reached 40–50 mm3, mice were randomly allocated into three
groups for further analysis. The treatment procedures used in this study had been
described in the Fig. 4e. Xenografts specimens were fixed with 10% formalin,
embedded in paraffin for cutting, and processed for IHC staining or were directly
frozen into liquid nitrogen for further analysis.
Generation of hCD147TG transgenic mice. We developed a humanized NSG
mouse model in which hCD147-specific CAR-T/NK cells could be adoptively
transferred into mice whose normal cells and tissue express an hCD147 transgene
at heterozygous or homozygous levels (Supplementary Fig. 17). Specifically, a
human cDNA encoding CD147 was targeted to mouse CD147 exon 1. The
resulting knock-in created a fusion protein composed of the first 22 amino acids of
the mouse CD147 signal peptide and amino acids 23–385 of the hCD147
(NP_001719.2) expressed under the control of the endogenous mouse CD147
promoter. Transcription termination was mediated by a bovine growth hormone
polyadenylation signal sequence. Targeting was performed directly in NSG mouse
embryos (JAX stock# 005557) by coinjecting a targeting vector and Cas9 protein
complexed with a CRISPR sgRNA recognizing and cutting the sequence 5′-
GCCTGCGCGGCGGGTAAGAG-3′. The targeted alleles were subsequently
sequenced in their entirety by PCR genotyping, and 14 positive founders were
correctly targeted.
Statistical analysis. Tumor size statistical analysis was performed by two-way
ANOVA (analysis of variance) with Bonferroni post tests. The overall survival
statistics were calculated using the log-rank test. Other statistical significance was
determined using a two-tailed unpaired Student’s t test or a two-tailed paired
Student’s t test. All statistical calculation graphs were generated by GraphPad
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Prism 5.0. P < 0.05 (*), P < 0.01(**), and P < 0.001(***) were considered statisti-
cally significant.
Data availability
Patient survival data and RNA-seq by expectation maximization normalized expression
datasets were downloaded from OncoLnc [http://www.oncolnc.org/] or from FireHose
Broad GDAC [https://gdac.broadinstitute.org/]. All remaining relevant data are available
in the article, Supplementary information, or from the corresponding author upon
reasonable request. Source data are provided with this paper.
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